Provinces reject federal call for prosecution of over-prescribing physicians

Miller, Adam

doi:10.1503/cmaj.109-4377

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shortly after release of the CFPC guideline for opioid prescribing, the federal government attempted to secure the ability to criminally charge physicians for their prescribing practices; however, this was prevented by provincial authority for health care oversight (Miller, 2013). Despite preventing criminal prosecution of physicians, provincial regulatory bodies increased surveillance of prescribers and patients alike, often with a punitive lens.…”

Section: Background and Contextmentioning

confidence: 99%

“…Complicating unclear guidance and general stigma, SS represents a dramatic departure from recent history in which less radical use of prescription opioids regularly resulted in punitive measures for prescriber and patient alike (Kotalik, 2012;Miller, 2013;Ross, 2020). Personal practice experience has seen the opioid prescribing practices of colleagues implementing SS investigated by the College of Physicians and Surgeons of BC.…”

Section: Safe Supplymentioning

confidence: 99%

See 1 more Smart Citation

Benefits people experiencing opioid use disorder derive from opioid agonist therapies

Orser¹

View full text Add to dashboard Cite

Opioid use disorder has become an epidemic over the past 20 years. Contamination of the street sourced drug supply with fentanyl and fentanyl analogues has resulted in a substantial increase in the associated overdose rate. Evidence-based treatments exist; however, much of the evidence supporting their use is based on demonstrations of mortality benefit, abstinence rates, treatment retention and cravings reductions. While these are important outcomes, they do not provide a complete picture of the benefit patients derive from these outcomes. As novel approaches and therapeutic agents are brought into practice, a more thorough understanding of the beneficial outcomes derived from existing therapies is needed both to guide implementation and improve access to therapy. Using the methodology of an integrative review this paper seeks to answer the question: beyond mortality benefit, treatment retention, craving reduction, and abstinence, what beneficial outcomes do people experiencing opioid use disorder derive from opioid agonist therapy? The findings of this review, while limited by the both the quantity and quality of evidence found, suggest that beneficial outcomes of opioid agonist therapy include improved mental and physical health, increased economic participation, reduced criminal activity, and improved quality of life. Associated recommendations for integrating the findings into clinical practice, policy, and research are discussed.iii

show abstract

Section: Background and Contextmentioning

confidence: 99%

Section: Safe Supplymentioning

confidence: 99%

Benefits people experiencing opioid use disorder derive from opioid agonist therapies

Orser¹

View full text Add to dashboard Cite

show abstract

Provinces reject federal call for prosecution of over-prescribing physicians

Cited by 1 publication

References 0 publications

Benefits people experiencing opioid use disorder derive from opioid agonist therapies

Benefits people experiencing opioid use disorder derive from opioid agonist therapies

Contact Info

Product

Resources

About